Use of quetiapine in bipolar disorder: A case series with prospective evaluation

T. Suppes, S. L. McElroy, P. E. Keck, L. Altshuler, Mark A Frye, H. Grunze, G. S. Leverich, W. A. Nolen, K. Chisholm, E. B. Dennehy, R. M. Post

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Quetiapine, a new atypical antipsychotic, was added to ongoing treatment of bipolar I outpatients (n=15) for symptoms of illness (mood lability, irritability, psychosis and/ or difficulty sleeping). All evaluations were prospectively obtained, with the majority of patients (n=9) showing much or very much improvement on the Clinical Global Impression for Bipolar Disorder (CGI-BP). Somatic complaints were limited. Mean (SD) duration before changes in medication regimens was 134 (100) days. Studies of the use of quetiapine in maintenance treatment of bipolar disorder are warranted.

Original languageEnglish (US)
Pages (from-to)173-174
Number of pages2
JournalInternational Clinical Psychopharmacology
Volume19
Issue number3
DOIs
StatePublished - May 2004
Externally publishedYes

Fingerprint

Bipolar Disorder
Psychotic Disorders
Antipsychotic Agents
Outpatients
Therapeutics
Quetiapine Fumarate

Keywords

  • Bipolar disorder
  • Maintenance
  • Outpatient
  • Polypharmacy
  • Quetiapine
  • Treatment

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)
  • Neuroscience(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Use of quetiapine in bipolar disorder : A case series with prospective evaluation. / Suppes, T.; McElroy, S. L.; Keck, P. E.; Altshuler, L.; Frye, Mark A; Grunze, H.; Leverich, G. S.; Nolen, W. A.; Chisholm, K.; Dennehy, E. B.; Post, R. M.

In: International Clinical Psychopharmacology, Vol. 19, No. 3, 05.2004, p. 173-174.

Research output: Contribution to journalArticle

Suppes, T, McElroy, SL, Keck, PE, Altshuler, L, Frye, MA, Grunze, H, Leverich, GS, Nolen, WA, Chisholm, K, Dennehy, EB & Post, RM 2004, 'Use of quetiapine in bipolar disorder: A case series with prospective evaluation', International Clinical Psychopharmacology, vol. 19, no. 3, pp. 173-174. https://doi.org/10.1097/00004850-200405000-00010
Suppes, T. ; McElroy, S. L. ; Keck, P. E. ; Altshuler, L. ; Frye, Mark A ; Grunze, H. ; Leverich, G. S. ; Nolen, W. A. ; Chisholm, K. ; Dennehy, E. B. ; Post, R. M. / Use of quetiapine in bipolar disorder : A case series with prospective evaluation. In: International Clinical Psychopharmacology. 2004 ; Vol. 19, No. 3. pp. 173-174.
@article{3e90ad82deda4c5fb0cd5849225f68e7,
title = "Use of quetiapine in bipolar disorder: A case series with prospective evaluation",
abstract = "Quetiapine, a new atypical antipsychotic, was added to ongoing treatment of bipolar I outpatients (n=15) for symptoms of illness (mood lability, irritability, psychosis and/ or difficulty sleeping). All evaluations were prospectively obtained, with the majority of patients (n=9) showing much or very much improvement on the Clinical Global Impression for Bipolar Disorder (CGI-BP). Somatic complaints were limited. Mean (SD) duration before changes in medication regimens was 134 (100) days. Studies of the use of quetiapine in maintenance treatment of bipolar disorder are warranted.",
keywords = "Bipolar disorder, Maintenance, Outpatient, Polypharmacy, Quetiapine, Treatment",
author = "T. Suppes and McElroy, {S. L.} and Keck, {P. E.} and L. Altshuler and Frye, {Mark A} and H. Grunze and Leverich, {G. S.} and Nolen, {W. A.} and K. Chisholm and Dennehy, {E. B.} and Post, {R. M.}",
year = "2004",
month = "5",
doi = "10.1097/00004850-200405000-00010",
language = "English (US)",
volume = "19",
pages = "173--174",
journal = "International Clinical Psychopharmacology",
issn = "0268-1315",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Use of quetiapine in bipolar disorder

T2 - A case series with prospective evaluation

AU - Suppes, T.

AU - McElroy, S. L.

AU - Keck, P. E.

AU - Altshuler, L.

AU - Frye, Mark A

AU - Grunze, H.

AU - Leverich, G. S.

AU - Nolen, W. A.

AU - Chisholm, K.

AU - Dennehy, E. B.

AU - Post, R. M.

PY - 2004/5

Y1 - 2004/5

N2 - Quetiapine, a new atypical antipsychotic, was added to ongoing treatment of bipolar I outpatients (n=15) for symptoms of illness (mood lability, irritability, psychosis and/ or difficulty sleeping). All evaluations were prospectively obtained, with the majority of patients (n=9) showing much or very much improvement on the Clinical Global Impression for Bipolar Disorder (CGI-BP). Somatic complaints were limited. Mean (SD) duration before changes in medication regimens was 134 (100) days. Studies of the use of quetiapine in maintenance treatment of bipolar disorder are warranted.

AB - Quetiapine, a new atypical antipsychotic, was added to ongoing treatment of bipolar I outpatients (n=15) for symptoms of illness (mood lability, irritability, psychosis and/ or difficulty sleeping). All evaluations were prospectively obtained, with the majority of patients (n=9) showing much or very much improvement on the Clinical Global Impression for Bipolar Disorder (CGI-BP). Somatic complaints were limited. Mean (SD) duration before changes in medication regimens was 134 (100) days. Studies of the use of quetiapine in maintenance treatment of bipolar disorder are warranted.

KW - Bipolar disorder

KW - Maintenance

KW - Outpatient

KW - Polypharmacy

KW - Quetiapine

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=2342512827&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2342512827&partnerID=8YFLogxK

U2 - 10.1097/00004850-200405000-00010

DO - 10.1097/00004850-200405000-00010

M3 - Article

C2 - 15107662

AN - SCOPUS:2342512827

VL - 19

SP - 173

EP - 174

JO - International Clinical Psychopharmacology

JF - International Clinical Psychopharmacology

SN - 0268-1315

IS - 3

ER -